Mirum Pharmaceuticals (MEX:MIRM) Other Long-Term Liabilities: MXN1,258 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
49 GF Score
Price MXN1,256.12
GF Value MXN1,071.10
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Other Long-Term Liabilities?

Mirum Pharmaceuticals MEX:MIRM 49 Other Long-Term Liabilities is MXN1,258 Mil as of Jun. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 49/100 and a GF Value™ of MXN1,071.10. The stock has 5 warning signs investors should review.

Mirum Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2026 was MXN1,258 Mil.

Mirum Pharmaceuticals's quarterly other long-term liabilities increased from Dec. 2025 (MXN90 Mil) to Mar. 2026 (MXN977 Mil) and increased from Mar. 2026 (MXN977 Mil) to Jun. 2026 (MXN1,258 Mil).

Mirum Pharmaceuticals's annual other long-term liabilities declined from Dec. 2023 (MXN65 Mil) to Dec. 2024 (MXN52 Mil) but then increased from Dec. 2024 (MXN52 Mil) to Dec. 2025 (MXN90 Mil).

Mirum Pharmaceuticals Other Long-Term Liabilities Related Terms

Mirum Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Other Long-Term Liabilities Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 0.35 88.36 65.33 52.33 90.23

Mirum Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.48 293.16 90.23 976.87 1,257.57
MEX:MIRM
49GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of MXN1,258 Mil mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Other Long-Term Liabilities of MXN1,258 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Other Long-Term Liabilities too high?
Mirum Pharmaceuticals' current Other Long-Term Liabilities is MXN1,258 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Other Long-Term Liabilities compare to COGT and RYTM?
Mirum Pharmaceuticals' Other Long-Term Liabilities of MXN1,258 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Other Long-Term Liabilities is MXN1,258 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Other Long-Term Liabilities of MXN1,258 Mil. The stock's GF Value™ is MXN1,071.10, compared to a current price of MXN1,256.12 — trading 17.3% above its estimated fair value. The current Other Long-Term Liabilities is MXN1,258 Mil. Mirum Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Other Long-Term Liabilities is MXN1,258 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 17.3% above its estimated GF Value™ of MXN1,071.10.

Key valuation signals for MEX:MIRM:

  • Other Long-Term Liabilities: MXN1,258 Mil
  • GF Value™: MXN1,071.10 vs. price of MXN1,256.12 (17.3% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
49GF Score

Get the complete analysis for MEX:MIRM

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN1,071.10
GF Value